SCHEMBL256812

SCHEMBL256812

Cc1cccc(C(=O)c2cccn2C)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
HSD17B10 Q99714 1/20 0.51
RAB9A P51151 3/20 0.43
LMNA P02545 3/20 0.41
PLA2G1B P04054 1/20 0.41
MAPT P10636 1/20 0.41
NPY1R P25929 1/20 0.41
HTT P42858 1/20 0.41
NPY2R P49146 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
NPC1 O15118 2/20 0.40
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15100731 0.83 SMN1; SMN2 (0.48) SMN1; SMN2HSD17B10RAB9ALMNAMAPT
SCHEMBL15197232 0.81 SMN1; SMN2 (0.47) SMN1; SMN2HSD17B10RAB9ALMNAPLA2G1B
SCHEMBL257536 0.78 SMN1; SMN2 (0.44) SMN1; SMN2HSD17B10RAB9ALMNAKDM4E
SCHEMBL11725781 0.78 SMN1; SMN2 (0.45) SMN1; SMN2HSD17B10RAB9ALMNAMAPT
SCHEMBL310386 0.78 KMT2A (0.52) SMN1; SMN2HSD17B10RAB9ALMNAMAPT
SCHEMBL29515031 0.78 KMT2A (0.52) SMN1; SMN2HSD17B10RAB9ALMNAMAPT
SCHEMBL526662 0.78 SMN1; SMN2 (0.58) SMN1; SMN2HSD17B10RAB9AMAPTALDH1A1
SCHEMBL11245998 0.76 SMN1; SMN2 (0.54) SMN1; SMN2HSD17B10RAB9AALDH1A1NPC1
Benzene SCHEMBL27738764 0.76 KMT2A (0.55) HSD17B10RAB9ALMNAHTTKDM4E
SCHEMBL31369360 0.75 SMN1; SMN2 (0.53) SMN1; SMN2HSD17B10RAB9AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 SMN1; SMN2 2704/4885HSD17B10 146/4885RAB9A 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.